Back to Research

Organization profile

Memo Therapeutics

Memo Therapeutics AG is a late-stage Swiss biotech company specializing in the discovery and development of best-in-class therapeutic antibodies derived from the immune repertoires of "elite" human responders. The company’s lead program, potravitug, targets BK polyomavirus infection in kidney transplant recipients and is moving toward Phase III clinical trials.

Schlieren, SwitzerlandFounded 2012

Overview

1. Executive Summary (Confidence: High)

Memo Therapeutics (MTx) is a late-stage biotechnology company that has pioneered a proprietary platform, DROPZYLLA, to translate unique human immune responses into superior medicines.[6] By capturing the antibody repertoires of "elite responders"—individuals who exhibit exceptional natural immunity to viral infections or cancer—MTx identifies highly potent antibodies that have been optimized by the human immune system.[6] The company’s lead asset, potravitug, has demonstrated significant efficacy in Phase II trials for the treatment of BK polyomavirus (BKPyV) infection in kidney transplant recipients, a condition with high unmet medical need that directly impacts organ longevity.[8] A major strategic milestone was achieved in February 2026 with a $328 million collaboration and option agreement with CSL to develop recombinant polyclonal IgG technology, further validating the industrial scalability of MTx’s platform.[10] With a strong financial backing, including a CHF [45] million Series C, and recent orphan drug designations in the EU, MTx is positioned as a critical player in the longevity of transplant medicine and precision oncology.[6]

This is an extract of the full organization profile. To access the full company profile, .

Desktop only

Research is currently available on desktop only.

The Research module is designed for larger screens. Please reopen it on a desktop or laptop to use the screener, filters, detail pages, and admin tools.